InvestorsHub Logo
Followers 191
Posts 6446
Boards Moderated 0
Alias Born 12/20/2011

Re: None

Sunday, 10/19/2014 11:08:42 AM

Sunday, October 19, 2014 11:08:42 AM

Post# of 113853
"In addition to the generic pharmaceutical business unit we are putting into place, we are moving full speed ahead with the development of our flagship proprietary anticancer drug, Adva-27a," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "Not unlike other fully integrated pharmaceutical companies, Sunshine plans to fund its proprietary drug development program through the sale of generic pharmaceuticals around the world. This is an important strategic positioning of the Company in order to become less dependent, if at all, on capital markets for the financing of our operations."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SBFM News